A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys and Copegus versus Pegasys and Copegus alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.

Trial Profile

A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys and Copegus versus Pegasys and Copegus alone in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Danoprevir (Primary) ; Ritonavir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms DAUPHINE
  • Sponsors Roche
  • Most Recent Events

    • 18 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Planned End Date changed from 1 Mar 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top